ipatasertib
Small moleculeexperimental
Ipatasertib (RG7440) is an experimental cancer drug in development by Roche. It is a small molecule inhibitor of AKT, which is a key component of the PI3K/AKT pathway. Ipatasertib was discovered by Genentech in collaboration with Array Biopharma and is currently in phase III trials for treatment of breast cancer. — Wikipedia
Clinical trial activity
56 trials · 42 clinical orgs · 0 marketing orgs
Phase 1
26
Phase 2
41
Phase 3
6
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01090960)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 1
- Breast Neoplasms · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Squamous Cell · Phase 2
- Circulating Tumor DNA · Phase 2
- Endometrial Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- Glioblastoma · Phase 1/Phase 2
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 1
- Healthy Volunteers · Phase 1
- Hepatic Insufficiency · Phase 1
- Hypopharyngeal Neoplasms · Phase 2
- Laryngeal Neoplasms · Phase 2
- Lymphoma · Phase 2
- Mouth Neoplasms · Phase 2
- Multiple Myeloma · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasm, Residual · Phase 2
- Neoplasms · Phase 3
- Oropharyngeal Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 3
Mechanism of action
- Serine/threonine-protein kinase AKTINHIBITOR
Serine/threonine-protein kinase AKT inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1- Mol. weight
- 458.01 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIpatasertib ↗
- ChEMBLCHEMBL2177390 ↗
Also known as
- 2-(4-chlorophenyl)-1-(4-(7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
- gdc-0068
- gdc-0068
- gdc-0068
- gdc-0068
- ipatasertib
- ipatasertib
- ipatasertib
- ipatasertib
- rg-7440
- rg-7440
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05862285 | Phase 3 | Jun 1, 2023 | Roche |
| NCT05538897 | Phase 1/Phase 2 (Phase 2) | Jan 13, 2023 | National Cancer Institute (NCI), NRG Oncology |
| NCT05332561 | Phase 2 | Dec 31, 2022 | German Cancer Research Center, Technical University of Munich |
| NCT05554380 | Phase 2 | Dec 9, 2022 | National Cancer Institute (NCI), Southwest Oncology Group |
| NCT05564377 | Phase 2 | Dec 9, 2022 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT05276973 | Phase 1 | Jun 27, 2022 | National Cancer Institute (NCI), NRG Oncology |
| NCT05172258 | Phase 2 | Apr 15, 2022 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT05172245 | Phase 1 | Apr 12, 2022 | National Cancer Institute (NCI), University of Toronto |
| NCT05180006 | Phase 2 | Feb 24, 2022 | Institut Gustave Roussy, Roche |
| NCT04931342 | Phase 2 | Oct 7, 2021 | European Network for Gynaecological Oncological Trial, GOG Foundation, Inc., Roche |
| NCT04920708 | Phase 2 | Aug 31, 2021 | Pfizer, Roche, Royal Marsden Hospital NHS Trust |
| NCT04737109 | Phase 1/Phase 2 (Phase 2) | Jul 13, 2021 | Big Ten Cancer Research Consortium, Northwestern University |
| NCT04802759 | Phase 1/Phase 2 (Phase 2) | Jun 20, 2021 | Roche |
| NCT04739202 | Phase 2 | Mar 19, 2021 | University of Lyon |
| NCT04632992 | Phase 2 | Dec 31, 2020 | Genentech |
| NCT04650581 | Phase 3 | Dec 31, 2020 | British Columbia Cancer Agency, Canadian Cancer Trials Group, Roche |
| NCT04589845 | Phase 2 | Nov 30, 2020 | Roche |
| NCT04551521 | Phase 2 | Nov 1, 2020 | German Cancer Research Center, NCT Studienzentrale |
| NCT04464174 | Phase 2 | Oct 8, 2020 | MedSIR, Roche |
| NCT04591431 | Phase 2 | Oct 7, 2020 | University of Roma La Sapienza |
Showing 20 of 56 trials
Page 1 / 3
Organizations
Research & Development (42)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 30 | 17 | 3 | 2014 |
| Genentech | For profit | 15 | 12 | 2 | 2010 |
| National Cancer Institute (NCI) | Government | 8 | 7 | 2 | 2019 |
| MedSIR | Academic/Hospital | 3 | 1 | 1 | 2017 |
| University of London | Academic/Hospital | 3 | 3 | 1 | 2017 |
| British Columbia Cancer Agency | Academic/Hospital | 2 | 0 | 2 | 2017 |
| Canadian Cancer Trials Group | Academic/Hospital | 2 | 2 | 2 | 2017 |
| City of Hope National Medical Center | Academic/Hospital | 2 | 1 | 1 | 2019 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Foundation Medicine | For profit | 2 | 0 | 1 | 2018 |
| German Cancer Research Center | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Harvard University | Academic/Hospital | 2 | 2 | 2 | 2019 |
| NRG Oncology | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Pfizer | For profit | 2 | 0 | 1 | 2020 |
| SOLTI Breast Cancer Research Group | Academic/Hospital | 2 | 1 | 2 | 2015 |
| Alliance Foundation Trials | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Big Ten Cancer Research Consortium | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Canadian Cancer Clinical Trials Network | Academic/Hospital | 1 | 0 | 1 | 2017 |
| European Network for Gynaecological Oncological Trial | Academic/Hospital | 1 | 0 | 1 | 2021 |
| GOG Foundation, Inc. | Academic/Hospital | 1 | 0 | 1 | 2021 |
42 organizations
Page 1 / 3